New Clinical End-points in Patients With Primary Sjögren's Syndrome

NCT05113004 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Primary Sjögren's Syndrome (pSS)

Interventions

DRUG: Hydroxychloroquine 400mg/d
DRUG: Leflunomide 20mg/d
DRUG: Mycophenolate mofetil 2000mg/d
DRUG: Placebo of Hydroxychloroquine 400mg/d
DRUG: Placebo of Leflunomide 20mg/d
DRUG: Placebo of Mycophenolate mofetil 2000mg/d

Sponsor

Assistance Publique - Hôpitaux de Paris